Kesios' series A brings L19M

Kesios Therapeutics Ltd. (London, U.K.) closed a L19 million ($28.5 million) series A round led by existing investor Imperial Innovations Group plc (LSE:IVO). New investors SV Life Sciences and Abingworth also participated.

Chairman and newly appointed CEO Paolo Paoletti told BioCentury that Kesios expects lead candidate KES-0001 to enter Phase I testing in 1H16 to treat multiple myeloma (MM). ...